Rationale: Retinopathy of Prematurity (ROP) remains a serious public health problem causing significant visual sequelae. It is estimated that 2,060 premature survivors in 1991 in the United States would be adversely affected by ROP, despite the now recognized use of Cryotherapy (estimates prior to Cryotherapy would have been 4,480). Case control studies in premature infants, anecdotal reports of successful treatment of moderately severe ROP with oxygen, and studies conducted in an animal model which induced chronic (weeks-long) hypoxia by breathing 13% inspired oxygen (mean PaO2=38) during the model's healing process, suggest that hypoxia may be a critical factor associated with and perhaps influencing cases that progress rather than regress. This hypothesis is supported by the association of proliferative retinopathies with retinal hypoxia in other disorders such as diabetic or sickle cell retinopathy. These data justify testing of the hypothesis that Supplemental Therapeutic Oxygen for Prethreshold ROP (STOP-ROP) will reduce, by at least one third, the number of infants with one or both eyes progressing to Threshold ROP. Design: This is a randomized blinded multicenter study utilizing 24 centers. 880 infants who develop Prethreshold ROP (as defined by STOP- ROP, modified from the CRYO-ROP study) will receive continuous pulse oximetry saturation monitoring and be randomly assigned to oxygen administration at one of two specified oxygen levels, """"""""conventional"""""""" with pulse oximetry of 89-94% saturation vs """"""""supplemental"""""""" with pulse oximetry of 96-99% saturation . Their ROP status will be measured and recorded prospectively, and the primary outcome variable will be the proportion of infants who progress to Threshold ROP in at least one eye by 3 months after their expected date of full term delivery. Secondary outcome measures include other ophthalmic (e.g. retinal detachment, macular ectopia) and neonatal outcomes (e.g. growth, pulmonary status, length and cost of hospital stay). The projected sample size is compatible with a 2-3 year enrollment.

Project Start
1997-12-01
Project End
1998-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
26
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Robinson-Cohen, Cassianne; Bartz, Traci M; Lai, Dongbing et al. (2018) Genetic Variants Associated with Circulating Fibroblast Growth Factor 23. J Am Soc Nephrol 29:2583-2592
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Srinivasan, Lakshmi; Page, Grier; Kirpalani, Haresh et al. (2017) Genome-wide association study of sepsis in extremely premature infants. Arch Dis Child Fetal Neonatal Ed 102:F439-F445
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Robarge, Jason D; Desta, Zereunesay; Nguyen, Anne T et al. (2017) Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Res Treat 161:453-461
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Patel, Yash R; Kirkman, M Sue; Considine, Robert V et al. (2017) Retinopathy predicts progression of fasting plasma glucose: An Early Diabetes Intervention Program (EDIP) analysis. J Diabetes Complications 31:605-610
Robarge, Jason D; Metzger, Ingrid F; Lu, Jessica et al. (2017) Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrob Agents Chemother 61:
Hertz, D L; Kidwell, K M; Seewald, N J et al. (2017) Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J 17:521-527
Kadakia, Kunal C; Kidwell, Kelley M; Seewald, Nicholas J et al. (2017) Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Res Treat 164:411-419

Showing the most recent 10 out of 767 publications